IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Analysis of Genetic Factors Which May Influence the Course of HIV Infection
This study has been completed.
Sponsor:
Deborah Rund
Information provided by (Responsible Party):
Deborah Rund, Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00159068
First received: September 9, 2005
Last updated: August 9, 2017
Last verified: August 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with HIV an have a variable course of their infection. We are trying to identify factors which worsen or ameliorate the course of the disease. Such factors may be related to metabolism (breakdown) of drugs or to iron handling by the body.
| Condition |
|---|
| HIV Infection |
| Study Type: | Observational |
| Study Design: | Observational Model: Other Time Perspective: Prospective |
| Official Title: | Genetic Influences on the Course and Response to Treatment of HIV: Contribution of Polymorphisms in Drug Metabolism and Disposition Genes and Haptoglobin Polymorphisms |
Resource links provided by NLM:
Further study details as provided by Deborah Rund, Hadassah Medical Organization:
Biospecimen Retention: Samples With DNA
Detailed Description:
DNA isolated from peripheral blood.
| Enrollment: | 100 |
| Study Start Date: | February 2004 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Patients with HIV can have a variable course and the disease may be influenced by polymorphisms in drug metabolism and disposition genes such as MDR1 and CYP3A4. In addition, reports have linked changes in the course of the disease with iron status, with high iron being detrimental. We will study polymorphisms in these genes and correlate with clinical course in HIV patients and also with phenotype of drug resistance and disease parameters (such as CD4 counts and opportunistic infections).
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with HIV attending the HIV clinic at Hadassah colden globes.
Criteria
Inclusion Criteria:
- diagnosis of HIV
Exclusion Criteria:
- under 18 years of age
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159068
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159068
Locations
| Israel | |
| Hadassah Medical Organization | |
| Jerusalem, Israel, IL91120 | |
Sponsors and Collaborators
Deborah Rund
Investigators
| Principal Investigator: | Deborah Rund, MD | Hadassah Medical Organization |
More Information
Publications:
| Responsible Party: | Deborah Rund, Senior Hematologist, Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00159068 History of Changes |
| Other Study ID Numbers: |
391200-HMO-CTIL |
| Study First Received: | September 9, 2005 |
| Last Updated: | August 9, 2017 |
Additional relevant MeSH terms:
|
Infection HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on August 18, 2017